These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 23230972

  • 21. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: is it effective?
    Goral S, Ynares C, Dummer S, Helderman JH.
    Kidney Int Suppl; 1996 Dec; 57():S62-5. PubMed ID: 8941924
    [Abstract] [Full Text] [Related]

  • 22. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L, Steinhoff J, Hartwig-Weber I, Bein G.
    Dtsch Med Wochenschr; 1997 May 02; 122(18):565-71. PubMed ID: 9190308
    [Abstract] [Full Text] [Related]

  • 23. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 May 02; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 24. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep 02; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D, Saldan A, Fiscon M, Cofano S, Paciolla A, Furian L, Ekser B, Biasolo MA, Cusinato R, Mengoli C, Bonfante L, Rossi B, Rigotti P, Sgarabotto D, Barzon L, Palù G.
    J Infect Dis; 2010 Aug 15; 202(4):585-94. PubMed ID: 20594105
    [Abstract] [Full Text] [Related]

  • 26. Long-term outcomes of cytomegalovirus infection and disease after lung or heart-lung transplantation with a delayed ganciclovir regimen.
    Thomas LD, Milstone AP, Miller GG, Loyd JE, Stephen Dummer J.
    Clin Transplant; 2009 Aug 15; 23(4):476-83. PubMed ID: 19453645
    [Abstract] [Full Text] [Related]

  • 27. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
    Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J.
    J Heart Lung Transplant; 1996 Sep 15; 15(9):881-7. PubMed ID: 8889983
    [Abstract] [Full Text] [Related]

  • 28. Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.
    Selvey LA, Lim WH, Boan P, Swaminathan R, Slimings C, Harrison AE, Chakera A.
    BMC Infect Dis; 2017 Jul 17; 17(1):501. PubMed ID: 28716027
    [Abstract] [Full Text] [Related]

  • 29. Cytomegalovirus infection in lung transplant patients: the role of prophylaxis and recipient-donor serotype matching.
    Burton CM, Kristensen P, Lützhøft R, Rasmussen M, Milman N, Carlsen J, Christiansen CB, Andersen CB, Iversen M.
    Scand J Infect Dis; 2006 Jul 17; 38(4):281-9. PubMed ID: 16715596
    [Abstract] [Full Text] [Related]

  • 30. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis.
    Limaye AP, Bakthavatsalam R, Kim HW, Randolph SE, Halldorson JB, Healey PJ, Kuhr CS, Levy AE, Perkins JD, Reyes JD, Boeckh M.
    Transplantation; 2006 Jun 27; 81(12):1645-52. PubMed ID: 16794529
    [Abstract] [Full Text] [Related]

  • 31. Cytomegalovirus viremia in lung transplantation during and after prophylaxis.
    Chang A, Musk M, Lavender M, Wrobel J, Yaw MC, Lawrence S, Chirayath S, Boan P.
    Transpl Infect Dis; 2019 Jun 27; 21(3):e13069. PubMed ID: 30884067
    [Abstract] [Full Text] [Related]

  • 32. Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.
    Devresse A, Leruez-Ville M, Scemla A, Avettand-Fenoel V, Morin L, Lebreton X, Tinel C, Amrouche L, Lamhaut L, Timsit MO, Zuber J, Legendre C, Anglicheau D.
    Transpl Infect Dis; 2018 Apr 27; 20(2):e12846. PubMed ID: 29360195
    [Abstract] [Full Text] [Related]

  • 33. Incidence and risk factors for cytomegalovirus disease in a Colombian cohort of kidney transplant recipients.
    Díaz J, Henao J, Rodelo J, García A, Arbeláez M, Jaimes F.
    Transplant Proc; 2014 Apr 27; 46(1):160-6. PubMed ID: 24507044
    [Abstract] [Full Text] [Related]

  • 34. High incidence of clinically significant cytomegalovirus infection in CMV D+/R+ lung transplant recipients receiving 3 months of antiviral prophylaxis.
    Kabbani D, Hirji A, Hernandez C, Malhi H, Mabilangan C, Chandrarathne S, Halloran K, Weinkauf J, Kapasi A, Lien D, Preiksaitis J, Cervera C.
    Transpl Infect Dis; 2019 Aug 27; 21(4):e13094. PubMed ID: 30985048
    [Abstract] [Full Text] [Related]

  • 35. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.
    Kruger RM, Paranjothi S, Storch GA, Lynch JP, Trulock EP.
    J Heart Lung Transplant; 2003 Jul 27; 22(7):754-63. PubMed ID: 12873543
    [Abstract] [Full Text] [Related]

  • 36. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial.
    Finlen Copeland CA, Davis WA, Snyder LD, Banks M, Avery R, Davis RD, Palmer SM.
    J Heart Lung Transplant; 2011 Sep 27; 30(9):990-6. PubMed ID: 21489817
    [Abstract] [Full Text] [Related]

  • 37. Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients.
    Opelz G, Döhler B.
    Transplantation; 2015 Jun 27; 99(6):1197-202. PubMed ID: 25606797
    [Abstract] [Full Text] [Related]

  • 38. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.
    Jaamei N, Koutsokera A, Pasquier J, Mombelli M, Meylan P, Pascual M, Aubert JD, Manuel O.
    Transpl Infect Dis; 2018 Aug 27; 20(4):e12893. PubMed ID: 29603543
    [Abstract] [Full Text] [Related]

  • 39. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients.
    Spivey JF, Singleton D, Sweet S, Storch GA, Hayashi RJ, Huddleston CB, Danziger-Isakov LA.
    Pediatr Transplant; 2007 May 27; 11(3):312-8. PubMed ID: 17430489
    [Abstract] [Full Text] [Related]

  • 40. Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis.
    Solidoro P, Patrucco F, Libertucci D, Verri G, Sidoti F, Curtoni A, Boffini M, Simonato E, Rinaldi M, Cavallo R, Costa C.
    Ther Adv Respir Dis; 2019 May 27; 13():1753466619878555. PubMed ID: 31566097
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.